• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

钙通道阻滞剂D - 600对心脏去甲肾上腺素储备的耗竭作用。

Depletion of cardiac noradrenaline stores by the calcium-channel blocker D-600.

作者信息

Chaudhry A, Vohra M M

出版信息

Can J Physiol Pharmacol. 1984 Jun;62(6):640-4. doi: 10.1139/y84-104.

DOI:10.1139/y84-104
PMID:6744107
Abstract

The actions of the calcium-channel blocker D-600 on cardiac noradrenaline stores were investigated by giving rats the drug systemically and then using a high-performance liquid chromatograph equipped with an electrochemical detector to determine the noradrenaline content of their hearts. A single 5-mg/kg dose of D-600 caused a significant depletion of noradrenaline content of the ventricles (approximately 31%) but not of the auricles. However, when multiple doses of D-600 were given at 12-h intervals, the depletion of cardiac noradrenaline content was more marked and both the auricular and ventricular contents were significantly decreased. Depletion of noradrenaline content was maximal 4 h after administration of D-600. A partial recovery of noradrenaline content occurred 16 h after administration of D-600, indicating that this effect of D-600 is reversible. In in vitro studies, D-600 (10(-7) to 10(-3) M) evoked a dose-related increase in the basal outflow of tritium from the rat isolated atria preloaded with [3H]noradrenaline ([3H]NA), indicating that depletion of cardiac noradrenaline stores by D-600 may be due to a direct action on sympathetic nerves rather than to increased reflex sympathetic activity secondary to profound vasodilation caused by the drug. The metabolic profile of tissue 3H content and of D-600-evoked 3H overflow was also examined. Whereas greater than 90% of tissue 3H content consisted of unchanged [3H]NA, 60-70% of the D-600-evoked overflow consisted of [3,4-3H]dihydroxyphenylglycol, and approximately 5% was unchanged NA, thus indicating that D-600 causes release of [3H]NA intraneuronally.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

通过对大鼠进行全身性给药,然后使用配备电化学检测器的高效液相色谱仪来测定其心脏中的去甲肾上腺素含量,研究了钙通道阻滞剂D - 600对心脏去甲肾上腺素储备的作用。单次给予5毫克/千克剂量的D - 600会导致心室去甲肾上腺素含量显著减少(约31%),但心房未出现这种情况。然而,当以12小时间隔多次给予D - 600时,心脏去甲肾上腺素含量的减少更为明显,心房和心室的含量均显著降低。给予D - 600后4小时,去甲肾上腺素含量的减少达到最大程度。给予D - 600后16小时,去甲肾上腺素含量出现部分恢复,这表明D - 600的这种作用是可逆的。在体外研究中,D - 600(10⁻⁷至10⁻³摩尔/升)引起预先用[³H]去甲肾上腺素([³H]NA)加载的大鼠离体心房中³H基础流出量呈剂量相关增加,这表明D - 600导致心脏去甲肾上腺素储备减少可能是由于对交感神经的直接作用,而不是由于该药物引起的深度血管扩张继发的反射性交感神经活动增加。还检查了组织³H含量和D - 600诱发的³H溢出的代谢情况。虽然超过90%的组织³H含量由未变化的[³H]NA组成,但D - 600诱发的溢出中60 - 70%由[3,4 - ³H]二羟基苯乙二醇组成,约5%是未变化的NA,因此表明D - 600在神经元内引起[³H]NA的释放。(摘要截断于250字)

相似文献

1
Depletion of cardiac noradrenaline stores by the calcium-channel blocker D-600.钙通道阻滞剂D - 600对心脏去甲肾上腺素储备的耗竭作用。
Can J Physiol Pharmacol. 1984 Jun;62(6):640-4. doi: 10.1139/y84-104.
2
Mechanism and metabolic disposition of verapamil-evoked overflow of radioactivity from isolated atria preloaded with [3H]norepinephrine.维拉帕米诱发预先用[3H]去甲肾上腺素加载的离体心房放射性溢出的机制及代谢处置。
J Pharmacol Exp Ther. 1985 Mar;232(3):850-6.
3
Inhibitory effects of verapamil, prenylamine and D 600 on Ca2+-dependent noradrenaline release from the sympathetic nerves of isolated rabbit hearts.维拉帕米、普尼拉明和D 600对离体兔心交感神经Ca2+依赖性去甲肾上腺素释放的抑制作用。
Naunyn Schmiedebergs Arch Pharmacol. 1979 Dec;310(1):11-9. doi: 10.1007/BF00499869.
4
Calcium antagonists and cardiac noradrenaline release in ischemia.钙拮抗剂与缺血时心脏去甲肾上腺素的释放
J Mol Cell Cardiol. 1991 Mar;23(3):269-77. doi: 10.1016/0022-2828(91)90063-r.
5
Short- and long-latency muscarinic inhibition of noradrenaline release from rabbit atria induced by vagal stimulation.迷走神经刺激诱导的兔心房去甲肾上腺素释放的短潜伏期和长潜伏期毒蕈碱抑制作用。
J Physiol. 1988 Jul;401:277-93. doi: 10.1113/jphysiol.1988.sp017162.
6
Involvement of pertussis toxin-sensitive and -insensitive mechanisms in alpha-adrenoceptor modulation of noradrenaline release from rat sympathetic neurones in tissue culture.百日咳毒素敏感和不敏感机制在组织培养中对大鼠交感神经元去甲肾上腺素释放的α-肾上腺素能受体调节中的作用。
Br J Pharmacol. 1993 Sep;110(1):281-8. doi: 10.1111/j.1476-5381.1993.tb13806.x.
7
Bay K 8644 enhances the outflow of [3H]-noradrenaline and [3H]-DOPEG from isolated rat atria.Bay K 8644增强了[3H]-去甲肾上腺素和[3H]-多巴胺从离体大鼠心房的流出。
Naunyn Schmiedebergs Arch Pharmacol. 1991 Jun;343(6):603-8. doi: 10.1007/BF00184291.
8
Sites of transmitter release and relation to intracellular Ca2+ in cultured sympathetic neurons.培养的交感神经元中递质释放位点及其与细胞内钙离子的关系。
Neuroscience. 1993 Feb;52(4):973-86. doi: 10.1016/0306-4522(93)90544-p.
9
Nonexocytotic release of endogenous noradrenaline in the ischemic and anoxic rat heart: mechanism and metabolic requirements.缺血缺氧大鼠心脏中内源性去甲肾上腺素的非胞吐释放:机制与代谢需求
Circ Res. 1987 Feb;60(2):194-205. doi: 10.1161/01.res.60.2.194.
10
The aziridinium derivative of DSP4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine) accelerates the beating rate of isolated rat atria by enhancing the spontaneous release of noradrenaline.DSP4的氮丙啶衍生物(N-(2-氯乙基)-N-乙基-2-溴苄胺)通过增强去甲肾上腺素的自发释放来加快离体大鼠心房的跳动速率。
Naunyn Schmiedebergs Arch Pharmacol. 1987 Oct;336(4):396-402. doi: 10.1007/BF00164872.

引用本文的文献

1
Effects of felodipine on the ischemic heart: insight into the mechanism of cytoprotection.非洛地平对缺血性心脏的影响:对细胞保护机制的深入了解。
Cardiovasc Drugs Ther. 1996 Sep;10(4):425-37. doi: 10.1007/BF00051107.
2
Effect of lacidipine on ischaemic and reperfused isolated rabbit hearts.拉西地平对离体兔缺血再灌注心脏的影响。
Mol Cell Biochem. 1993 Aug 11;125(1):73-86. doi: 10.1007/BF00926837.
3
Effect of D-600 on ischemic and reperfused rabbit myocardium: relation with timing and modality of administration.D-600对兔缺血再灌注心肌的影响:与给药时间和方式的关系。
Basic Res Cardiol. 1989 Nov-Dec;84(6):606-22. doi: 10.1007/BF01906946.
4
Prolonged protective effect of the calcium antagonist anipamil on the ischemic reperfused rabbit myocardium: comparison with verapamil.钙拮抗剂阿尼帕米对兔缺血再灌注心肌的长期保护作用:与维拉帕米的比较。
Cardiovasc Drugs Ther. 1989 Jun;3(3):403-12. doi: 10.1007/BF01858111.